This platform utilizes lymph node-derived cells to implement immune responses in 3D organoid models, realizing the concept of 'Clinical Trial in a Dish' through AI and robotic automation. Currently, eight global pharmaceutical companies are conducting preliminary validations, and preclinical tests for Centivax's influenza vaccine candidate have already been successfully completed. The platform is designed to be SaaS-based, allowing remote use from anywhere in the world, and boasts high precision and speed. Key investors include AIX Ventures, Amplo, and Salesforce founder Marc Benioff. The company has stated its vision to build an 'artificial immune system.' This is expected to be a turning point that can replace animal testing in various fields, including future immune therapy development, vaccine screening, and immunotoxicity assessment.